In this case, we first reported targeted comutation of somatic novel KANK1-ALK, UPP2 intergenic NTRK3 fusion, and pathogenetic germline BRCA1 mutation in a pancreatic ductal adenocarcinoma patient. This evidence concerns the gene NTRK3 and pancreatic ductal adenocarcinoma.